A recent study in BD examined the efficacy of immediate-release TOF 5 mg twice-daily therapy under preserved background medications in 13 patients with articular, cardiovascular, and/or gastrointestinal manifestations refractory to conventional disease modifying anti-rheumatic drugs.[7] Among them, 5 cases had ever received anti-TNF mAbs and 1 was treated earlier with an IL-6 blocker. Here, TNF is linked to Behcet disease.